Is the Achilles’ Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling?

Ivan V. Litvinov(McGill University Health Centre), John T. Isaacs(Brady (Norway))

The Journal of Clinical Endocrinology & Metabolism

July 1, 2003

10.1210/jc.2002-022038

Cited by 211

Related Papers

The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating Cells

|Cancer Research|2008|233

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

|PubMed|2003|124

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

|Cancer Research|2012|113

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

|Molecular Cancer|2010|90

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

|The Prostate|2006|87